Search

Displaying results 1231 - 1240 of 10000 in total
  1. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    [A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827] … Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery

    Mixtures: DUEDOM 30/10 MG KAPSÜL, 30 ADET, DUEDOM 60/10 MG KAPSÜL, 30 ADETCategories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.

    Products: CEREZYME 400 U/10 ML İNFÜZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ, CEREZYME 200 U INFUZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  3. Drug

    Nifuroxazide

    go.drugbank.com/drugs/DB13855
    Investigational

    Mixtures: METRONIDAZOL/NIFUROXAZIDA 300 MG/100 MG., DIARSET NX® M CAPSULASCategories: Heterocyclic Compounds, 1-Ring
  4. Drug

    L-2-amino-4-methoxy-cis-but-3-enoic acid

    go.drugbank.com/drugs/DB03611
    Experimental

    Synonyms: L-2-amino-4-methoxy-cis-but-3-enoic acid
  5. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease

    Products: ENTYVIO® 108 MG SOLUCIÓN INYECTABLE, ENTYVIO® (SUBCUTÁNEO) VEDOLIZUMAB 108 MG SOLUCIÓN INYECTABLE
  6. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. … [A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]

    Mixtures: Co-Dilatrend 25 mg/12,5 mg - FilmtablettenCategories: Adrenergic alpha-1 Receptor Antagonists, Adrenergic beta-1 Receptor Antagonists
  7. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.

    Products: MOZOBIL 20 MG/ ML ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADET, AUROPLERISTEM 20 MG/ML
  8. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803] … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.

    Categories: Heterocyclic Compounds, 1-RingProducts: Erigib 150 mg Sert Kapsül, 28 ADET, ERIVEDGE 150 MG SERT KAPSÜL ,28 KAPSÜL
  9. Drug

    5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine

    go.drugbank.com/drugs/DB02004
    Experimental

    Synonyms: 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine
  10. Drug

    3-(3-Methyl-2-buten-1-yl)-3H-purin-6-amine

    go.drugbank.com/drugs/DB08074
    Experimental

    Synonyms: 3-(3-Methyl-2-buten-1-yl)-3H-purin-6-amine